COMBIHALE SOLUTION

COMBIHALE SOLUTION is a medication that combines two active Ingrediants Ipratropium Bromide & Salbutamol (albuterol). Ipratropium bromide is an anticholinergic bronchodilator, and salbutamol is a beta2-adrenergic bronchodilator. Together, they work to relax and widen the airways in the lungs, making it easier to breathe.

Uses:

1. Bronchospasm:
   • COMBIHALE SOLUTION is used to relieve bronchospasm (narrowing of the airways) in conditions such as asthma and chronic obstructive pulmonary disease (COPD).
2. Chronic Obstructive Pulmonary Disease (COPD):
   • It is prescribed for the management of symptoms associated with COPD, including chronic bronchitis and emphysema.

Side Effects:

Common side effects of COMBIHALE SOLUTION may include:

• Dry mouth
• Cough
• Headache
• Nervousness
• Tremor

Serious side effects may include:

• Allergic reactions
• Increased heart rate
• Worsening of breathing difficulties

When Not to Use:

1. Hypersensitivity:
   • Individuals with a known hypersensitivity to ipratropium bromide, salbutamol, or any components of the formulation should avoid using COMBIHALE.

Precautions and Warnings:

• Cardiovascular Conditions:
  • Caution is advised in patients with pre-existing cardiovascular conditions, as salbutamol may lead to increased heart rate and blood pressure.
• Diabetes:
  • Salbutamol can affect blood glucose levels, and monitoring is recommended in patients with diabetes.
• Hypokalemia:
  • Salbutamol may cause a decrease in potassium levels, especially with high doses. Monitoring of potassium levels is advisable.
• Pregnancy and Breastfeeding:
  • The safety of COMBIHALE during pregnancy and breastfeeding should be discussed with a healthcare professional.

Dosage and Administration:

• The dosage of COMBIHALE should be individualized based on the patient’s condition and response to treatment. It is typically administered via inhalation.

Patients should follow their healthcare provider’s instructions regarding the proper use of the inhalation solution and report any adverse effects promptly. This information is not exhaustive, and healthcare providers should refer to the prescribing information for a comprehensive understanding of the medication.